Vertex Pharmaceuticals Incorporated
Capitalisation boursière
$130.6B
Rang mondial
#131
Sommet historique
$134.4B
2026-07-06
Croissance totale
+0%
depuis 2026
Market Cap Context
- Larger than 64% of the 367 companies we track (globally).
- Equivalent to 0.4% of United States's GDP (2025 data).
- Just above: #130 Bank of Montreal ($131.4B)
- Just below: #132 Stryker Corporation ($127.2B)
- Best year: 2000 (+309%). Worst year: 2001 (-66%).
Vertex Pharmaceuticals Incorporated Financial Breakdown (FY 2025)
Source: Yahoo Finance — VRTX annual filings (2025) →$12.0B revenue · $4.6B operating income · $4.0B net income
- ●Operating margin: 37.9% on $12.0B in revenue.
- ●R&D is 33.7% of revenue ($4.0B).
- ●Net income margin: 32.9% — $4.0B in profit.
- ●Free cash flow: $3.2B (26.6% of revenue).
Cost / Operating Expenses
Total operating expenses $7.4B
Total
$7.4B
Capital Expenditures
$0.4B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$3.2B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
À propos de Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Historique de la capitalisation boursière de Vertex Pharmaceuticals Incorporated (2026–2026)
Vertex Pharmaceuticals Incorporated vs Sector Peers by Market Cap
Comparer Vertex Pharmaceuticals Incorporated
Historique du classement
| Année | Capitalisation boursière | Rang | Variation sur un an |
|---|---|---|---|
| 2026 | $130.6B | #131(↑5) | +13.5% |
| 2025 | $115.1B | #136(↓7) | +12.6% |
| 2024 | $102.2B | #129(↓21) | -1.0% |
| 2023 | $103.3B | #108(↑17) | +40.9% |
| 2022 | $73.3B | #125(↑57) | +31.5% |
| 2021 | $55.7B | #182(↓39) | -7.1% |
| 2020 | $60.0B | #143(↓18) | +7.9% |
| 2019 | $55.6B | #125(↑3) | +32.1% |
| 2018 | $42.1B | #128(↑24) | +10.6% |
| 2017 | $38.0B | #152(↑70) | +103.4% |
| 2016 | $18.7B | #222(↓94) | -41.5% |
| 2015 | $31.9B | #128(↑2) | +5.9% |
| 2014 | $30.2B | #130(↑44) | +59.9% |
| 2013 | $18.9B | #174(↑28) | +77.3% |
| 2012 | $10.6B | #202 | +26.2% |
| 2011 | $8.4B | #202(↑4) | -5.2% |
| 2010 | $8.9B | #206(↓37) | -18.2% |
| 2009 | $10.9B | #169(↓4) | +41.0% |
| 2008 | $7.7B | #165(↑62) | +30.8% |
| 2007 | $5.9B | #227(↓49) | -37.9% |
| 2006 | $9.5B | #178(↑9) | +35.2% |
| 2005 | $7.0B | #187(↑43) | +161.8% |
| 2004 | $2.7B | #230(↓16) | +2.1% |
| 2003 | $2.6B | #214(↓54) | -34.7% |
| 2002 | $4.0B | #160(↓22) | -35.5% |
| 2001 | $6.2B | #138(↓69) | -65.6% |
| 2000 | $18.1B | #69(↑51) | +308.6% |
| 1999 | $4.4B | #120(↓2) | +17.6% |
| 1998 | $3.8B | #118(↓14) | -9.8% |
| 1997 | $4.2B | #104(↓35) | -18.0% |
| 1996 | $5.1B | #69(↑9) | +51.9% |
| 1995 | $3.4B | #78(↑1) | +76.7% |
| 1994 | $1.9B | #79 |
Autres entreprises du secteur Santé
FAQ
What is Vertex Pharmaceuticals Incorporated's market cap?
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of $130.6B, making it the #131 largest company in the world by market cap.
What was Vertex Pharmaceuticals Incorporated's highest market cap?
Vertex Pharmaceuticals Incorporated's all-time high market cap was $134.4B, reached in 2026-07-06. Its highest rank was #131 in 2026.
What sector is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated is in the Healthcare sector, specifically the Biotechnology industry. It is based in United States.
How has Vertex Pharmaceuticals Incorporated's market cap changed over time?
Vertex Pharmaceuticals Incorporated has been tracked since 2026. Its market cap has grown by 0% from $130.6B in 2026 to $130.6B today.